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Kathryn B. Garber1,*Gene-Specific Cancer Risk Estimates for Lynch
Syndrome
Although mutations in four separate genes can lead to the
Lynch syndrome, cancer risks for the syndrome have typi-
cally been estimated for the group as a whole. New data
indicate that the cancer risks differ depending on the
gene that is mutated and suggest that recommended
cancer surveillance strategies could be altered depending
on the gene involved. These data come from a study of
more than 500 French Lynch syndrome families segre-
gating mutations in MLH1, MSH2, or MSH6. Overall, the
colorectal cancer risk estimates were lower than reported
in many other studies, but they also differed depending
on the gene that was mutated. Not only was the colorectal
cancer risk estimate strikingly lower for MSH6 mutation
carriers, the age at diagnosis was also significantly older
than it was for MLH1 and MSH2 mutation carriers. MSH6
mutation carriers also have much lower estimated risks of
endometrial cancer and ovarian cancer; for these individ-
uals, the cumulative risk of ovarian cancer by age 70 is
only 1%. The onset and frequency of surveillance strate-
gies and the relative benefit of prophylactic surgeries for
Lynch syndrome are likely to be reassessed in light of these
findings and may in the future include mutation testing to
individualize the strategy based on the gene mutated in
a particular family.
Bonadana et al. JAMA 305: 2304–2310.
Fmrp and Mecp2: New Tricks in an Old Mouse
When a mutation causes autism and/or intellectual
disability, one could assume that the mutated gene is
crucial for proper neural development and focus solely
on its role in the prenatal period. Two recent studies
explored the role of two such genes, Mecp2 and Fmr1, in
mature animals and find evidence for continued function
in neurons of adult mice. McGraw et al. found that dele-
tion of Mecp2 in fully mature mice leads to motor symp-
toms and changes in gene expression and behavior that
are similar to those in mice that have always lacked the
gene. Zeroing in even further, Guo et al. identified a role
for Fmrp specifically in adult neural stem cells. Selective
deletion of Fmr1 in these cells alters their proliferation
and differentiation and leads to deficits in neurite exten-
sion as well as learning. Conversely, specific restoration
of Fmrp expression in the adult neural stem cells of Fmr1
knockout mice rescues the deficits in these mice. Both1Department of Human Genetics, Emory University School of Medicine, Atlan
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ment genes’’ into the adult period, which has implications
for the targeted treatment of individuals with Rett or
Fragile X syndrome, suggesting treatment may need to be
indefinite.
McGraw et al. Science Express. Published online June 2,
2011. 10.1126/science.1206593; Guo et al. Nature Medicine
17:559–565.
Molecular Link to Muscle Weakness in Myotonic
Dystrophy
Repeat-containing ‘‘toxic’’ RNAs cause myotonic dys-
trophy (DM) types 1 and 2 by sopping up RNA splice regu-
lators including Muscle-blind-like-1 (MBLN-1), leaving
them unable to properly regulate splicing of their targets.
Although a number of these misspliced targets have been
identified in DM1 and DM2, a clear picture by which this
leads to progressive muscle weakness has been lacking.
Fugier et al. recently identified a key link between
MBLN-1 sequestration and muscle weakness in DM:
BIN1. In individuals with DM, BIN1 RNA maintains an
embryonic pattern of splicing in which a key exon of the
muscle-specific isoform is excluded. Skipping this exon
yields a protein that is incapable of properly binding to
cell membranes and renders it unable to participate in
the formation of T tubules, which aremembrane structures
that are crucial for excitation-contraction coupling in
muscle. Supporting this model is the fact that mice in-
jected with an adeno-associated virus expressing an RNA
designed to recapitulate themissplicing of Bin1 hadmuscle
weakness in the injected limb.
Fugier et al. Nature Medicine 17: 720–725.
Newer Generation Antiepileptic Drugs
Do Not Increase Risk of Birth Defects
Despite the fact that up to 1 in 200 pregnant women take
antiepileptic medications during pregnancy, a thorough
assessment of the teratogenic effects of the newer classes
of these medications has been lacking. The extensive use
of medical registries in Denmark facilitated a systematic
study of this issue because it allowed connection of data
from registries of births, medication prescriptions, and
patient data in order to assess the safety of fetal exposure
to these drugs during the first trimester. The overall data
in this analysis by Molgaard-Nielsen and Hviid included
more than 800,000 births that spanned 12 years. Theta, GA 30322, USA
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more than 1,500 mothers who were prescribed lamotri-
gine, oxcarbazepine, topiramate, gabapentin, or levetirace-
tam in the first trimester of pregnancy could be compared
with the 836,000 mothers not given those drugs during
pregnancy. No association between the use of these drugs
during the first trimester and major birth defects was
found, once adjustment for use of older-generation antiep-
ileptic drugs and epilepsy was made. When subtypes of
birth defects were examined, the only positive association
was between lamotrigine and an increased risk of eye
defects. However, these defects were found in only four
infants, and each of the four defects was etiologically
distinct, suggesting this was not a causal finding. This
study should increase the confidence of physicians
prescribing these medications during pregnancy.
Molgaard-Nielsen and Hviid. JAMA 305:1996–2002.
Rare Sensitivity to Vitamin D Supplementation
Explained
Public health strategies are aimed at doing the most
good to the most people while also limiting harm. One
of the most successful examples is vitamin D supplemen-
tation of milk, which was implemented in the 1930s4 The American Journal of Human Genetics 89, 3–4, July 15, 2011and has since led to a precipitous decline in the incidence
of rickets. However, during the mid-20th century, as the
recommended level of vitamin D supplementation was
being settled upon and some countries were recommend-
ing quite large doses, there was a spike in cases of idio-
pathic infantile hypercalcemia, a potentially fatal condi-
tion that was caused by an apparent hypersensitivity
to vitamin D. Using a targeted sequencing strategy,
Schlingmann et al. recently uncovered mutations respon-
sible for this sensitivity. These recessive mutations in
CYP24A1—which encodes a key enzyme for breakdown
of vitamin D—render the enzyme nonfunctional, or
nearly so. Reductions to the recommended daily dose of
vitamin D have already led to large declines in the
number of cases of idiopathic infantile hypercalcemia,
but it should be noted that half of the affected children
in this study received daily doses of 500 IU, which is
still considered a safe dose. Although the benefit of
vitamin D supplementation to the public health is unar-
guable, there are very rare outliers who may be sensitive
to this supplementation.
Schlingmann et al. NEJM. Published online June 15, 2011.
10.1056/NEJMoa1103864.This Month in Our Sister JournalsAVariant of Known Significance in CCM2
What can be done when the meaning of a DNA sequence
cannot be extracted? If a sequence variant in a disease gene
doesn’t have an obvious effect on a codon or regulatory
motif, how should it be used for risk analysis? Such was
the case for a two-base pair change in CCM2 that has
been reported in seven unrelated individuals of Ashkenazi
Jewish descent who were diagnosed with cerebral
cavernous malformation (CCM) by MRI. CCM are vascular
defects in the central nervous system that are associated
with an unpredictable risk of hemorrhage. Autosomal-
dominant mutations in three different genes can cause
these malformations, which remain asymptomatic in
some people but may also lead to severe headaches,
intractable epilepsy, and stroke. At-risk relatives can be
screened by MRI, but the fact that the number and size
of lesions generally increase with age means this has to
be done on a periodic basis. To limit the burden of thisscreening, molecular analysis can be used for identifying
mutation carriers in affected families, but, in the case of
a variant of unknown significance, testing of at-risk rela-
tives cannot be pursued. Sometimes, the variant can be
enlightened by further molecular analysis. This is just
what was done by Gallione et al., who were able to clarify
that the CCM2 variant is a disease-causing mutation that
is likely to be a fairly common cause of CCM in the
Ashkenazi Jewish population. The variant alters splice
donor site utilization, yielding an altered transcript
that is subject to degradation. The ambiguity of a variant
of uncertain significance is a frustrating outcome for
patients and families seeking genetic risk analysis for
many genetic disorders. Although not always practical,
further molecular analysis such as this can help to alleviate
this frustration.
Gallione et al. Genetics in Medicine. Published online May 3,
2011. 10.1097/GIM.0b013e318211ff8b.
